Recce Pharmaceuticals Ltd (ASX:RCE)

Australia flag Australia · Delayed Price · Currency is AUD
0.440
-0.020 (-4.35%)
Mar 9, 2026, 2:00 PM AEST
18.92%
Market Cap 133.02M
Revenue (ttm) 974.56K
Net Income (ttm) -30.25M
Shares Out 289.18M
EPS (ttm) -0.11
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 86,193
Average Volume 72,303
Open 0.450
Previous Close 0.460
Day's Range 0.440 - 0.455
52-Week Range 0.275 - 0.730
Beta 0.20
RSI 28.36
Earnings Date Feb 26, 2026

About Recce Pharmaceuticals

Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic anti–infectives in Australia, the United Kingdom, and the United States. The company’s lead candidate is RECCE 327 (R327) for the treatment of life-threatening bacterial infections. In addition, its product pipeline comprises R327 Intravenous, which is in Phase I and Phase I/II clinical trial for the treatment of urinary tract infections/urosepsis; and R327 Topical Gel, which is Phase II clinical trial for the treatment of acute bacterial skin and skin structure infect... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2007
Country Australia
Stock Exchange Australian Securities Exchange
Ticker Symbol RCE
Full Company Profile

Financial Performance

In fiscal year 2025, Recce Pharmaceuticals's revenue was 7.51 million, an increase of 49.33% compared to the previous year's 5.03 million. Losses were -21.43 million, 21.3% more than in 2024.

Financial Statements

News

There is no news available yet.